ARHGAP21

Across TCGA pan-cancer cohorts, ARHGAP21 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGAP21 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARHGAP21 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP21 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where ARHGAP21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.752	0.994	.001	42	view →
LSCC	DFS	Median	II,III,IV	0.865	0.970	.005	33	view →
PDAC	OS	Tertile	IV	0.405	0.828	.038	9	view →
HNSC	OS	Median	IV	0.590	0.855	.007	7	view →
GBM	OS	Quartile	All	0.654	0.421	.049	2	view →
CCRCC	DFS	Median	II,III,IV	0.839	0.964	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGAP21–LUAD (DFS)

Open the LUAD breakdown →